People with relapsed or refractory multiple myeloma often face limited options. A recent analysis looked at two new types of antibodies designed to target specific proteins on cancer cells. These treatments aim to help the immune system find and destroy the disease. The review combined data from 1,900 patients who received these therapies. It is important to note that the evidence comes mainly from single-arm trials and real-world studies, which means the certainty of the findings is low to very low.
The results show promise for some. About 66 percent of patients had an overall response to treatment. This included 38 percent achieving a complete response or better. For progression-free survival, the average time before the disease grew again was about 8.8 months. However, these numbers must be weighed against the side effects seen in this group.
Safety signals were significant. Nearly 68 percent of patients experienced cytokine release syndrome, a reaction where the immune system overreacts. More than 60 percent faced infections, and 38 percent had serious infections. Low white blood cell counts occurred in over half the patients, with serious cases in 43 percent. Because the evidence is limited, doctors should interpret these findings cautiously. Patients and families must pay close attention to infection risks and low blood counts when considering these options.